IDEXX Laboratories (NASDAQ:IDXX) President and CEO Michael Erickson used a Stifel investor conference appearance to emphasize the company’s innovation pipeline, expanding commercial reach and growing...
/Idexx%20Laboratories%2C%20Inc_%20phone%20and%20chart%20-by%20IgorGolovniov%20via%20Shutterstock.jpg)
Although IDEXX Laboratories has lagged the broader market over the past year, Wall Street analysts remain fairly bullish about the company’s long-term growth prospects.
Third menu expansion in four years broadens intestinal parasite detection in routine care
Built-in SDMA delivers earlier insights with seamless workflow
Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth...
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, will participate in a fireside chat at...
Achieves first quarter revenue growth of 14% as reported and 11% organic, and CAG Diagnostics recurring revenue growth of 14% as reported and 11% organic. ...
Barchart Research What to Expect from IDXX Earnings IDXX Generated May 4, 2026 Current Price $563.12 EPS Estimate $$3.42 Consensus Rating Moderate Buy Average Move 10.62% IDEXX Laboratories Set to Reveal...
/Idexx%20Laboratories%2C%20Inc_%20outside%20lab-by%20Sundry%20Photography%20via%20iStock.jpg)
IDEXX Laboratories is ready to release its fiscal first-quarter earnings next month, and analysts project a double-digit profit growth.